| Today's News and Trends | “We believe that any iatrogenic complication should be reported,” the study's authors wrote. “No patient expects to be discharged from hospital with a new diaphragmatic deficit without being informed." “We believe that any iatrogenic complication should be reported,” the study's authors wrote. “No patient expects to be discharged from hospital with a new diaphragmatic deficit without being informed." | | |
| Cardiology faces one of its most challenging decades ahead, with mounting pressures from workforce shortages, an aging population and declining reimbursements. To remain sustainable, practices are forced to rethink how care is delivered from the ground up. Cardiology faces one of its most challenging decades ahead, with mounting pressures from workforce shortages, an aging population and declining reimbursements. To remain sustainable, practices are forced to rethink how care is delivered from the ground up. | | |
| Positron made the move to help its case when it files an official Form 10 registration statement with the SEC. Positron made the move to help its case when it files an official Form 10 registration statement with the SEC. | | |
| | Australia-based Artrya Limited says its AI-enabled Salix Coronary Plaque module offers near real-time, point-of-care CCTA assessment and management of coronary artery disease. Australia-based Artrya Limited says its AI-enabled Salix Coronary Plaque module offers near real-time, point-of-care CCTA assessment and management of coronary artery disease. | | |
| "Eko is transforming how we detect cardiovascular disease—making cutting-edge, AI-powered tools accessible to frontline providers," said former U.S. Surgeon General Jerome Adams, MD. "Eko is transforming how we detect cardiovascular disease—making cutting-edge, AI-powered tools accessible to frontline providers," said former U.S. Surgeon General Jerome Adams, MD. | | |
| Greg Piefer, PhD, chief executive and founder of Shine, a Wisconsin-based radiopharmaceutical company that is building the world’s largest medical isotope production facility in Janesville, Wisconsin, explains progress on the company's fusion reactor that will become the first sustained U.S. commercial supplier of molybdenum-99 in decades. Greg Piefer, PhD, chief executive and founder of Shine, a Wisconsin-based radiopharmaceutical company that is building the world’s largest medical isotope production facility in Janesville, Wisconsin, explains progress on the company's fusion reactor that will become the first sustained U.S. commercial supplier of molybdenum-99 in decades. | | |
| | Customers with these devices on hand are asked to return them right away. No serious injuries have been reported at this time, but the presence of residual particulates can lead to such side effects as pulmonary embolism and deep vein thrombosis. Customers with these devices on hand are asked to return them right away. No serious injuries have been reported at this time, but the presence of residual particulates can lead to such side effects as pulmonary embolism and deep vein thrombosis. | | |
| A Signify Research representative highlights key trends in cardiovascular IT systems, including the growing role of AI and much more. A Signify Research representative highlights key trends in cardiovascular IT systems, including the growing role of AI and much more. | | |
| The FTC is working to stop Edwards Lifesciences from completing its acquisition of JenaValve. Edwards, however, is not backing down. The FTC is working to stop Edwards Lifesciences from completing its acquisition of JenaValve. Edwards, however, is not backing down. | | |
| | Most organizations trying out generative AI—a full 95%—are failing to receive a measurable return on the pilot investment. Most organizations trying out generative AI—a full 95%—are failing to receive a measurable return on the pilot investment. | | |
| If three sticking points aren’t unstuck soon, older Americans won’t benefit much by the 1,000+ medical devices that, as of 2025, are both equipped with AI and cleared by the FDA. If three sticking points aren’t unstuck soon, older Americans won’t benefit much by the 1,000+ medical devices that, as of 2025, are both equipped with AI and cleared by the FDA. | | |
| |
|
| ![]() | |
|
